Alpha Cognition Inc. - Common Stock (ACOG) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently mixed earnings tone.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
78
Good based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$8.30
Trend Context
Mixed / range
Latest briefing
What's happening with ACOG
businesswire.com10 Jul 2026
Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage & Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle & Vision Summit, taking place July 16th in Boston, Massachu.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
gurufocus.com23 Jun 2026
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Alpha Cognition Inc. (Nasdaq: ACOG) (âAlpha Cognitionâ, or the âCompanyâ), a biopharmaceutical company focused on developing novel therapies for debili
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
businesswire.com16 Jun 2026
Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's Disease
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (ACOG: NASDAQ) (“Alpha Cognition” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. RESOLVE is a mult.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
gurufocus.com
9 Jun 2026
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's Disease
